Newsletter | July 14, 2025

07.14.25 -- Innovation driving access in advanced therapies

Getting Genomic Medicines Ready For Prime Time

Reliable LNP production is crucial in transitioning the promising nucleic acid clinical pipeline into commercial production. Explore the benefits of building a manufacturing process early, how research into LNPs in nucleic acid therapeutics will contribute to the development of future drugs, and more.

 

Cost And Scalability Key Drivers Of Expanded Gene Therapy Access

Viral vector-based gene therapies have the potential to tackle more common indications with larger treatment populations and are expanding beyond rare diseases, but high costs hinder access. Discover how innovations in viral vector manufacturing could make these breakthroughs more affordable.

 

Nanomedicine Modalities Find Path To Clinic Through Analytics

Is the nanomedicine solutions space ready to support cutting-edge research and development? Lipid nanoparticles have revolutionized drug delivery and have ushered in a new era. Find out how advanced analytical tools are accelerating next-generation LNP therapeutics.

 

CAR T Set The Pace So All Can Win The Cell Therapy Race

It's been about 100 years since researchers have looked to the power of cells as a potential treatment. Gain insight into the modest origins of cell therapy manufacturing and how this history has paved the way for future advancements from Bill Shingleton, R&D Leader at Cytiva.

 

Genomic Medicine Demands Manufacturing Innovation

Genomic medicine, the therapeutic use of cells and genetic materials, is at the center of a medical revolution. Read about how the promise of novel therapeutic modalities can only be realized when effective science is paired with efficient manufacturing to provide cost-effective therapies to patients in need.